Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Improved Personalized Cancer Immunotherapy: Rapid Selection of Tumor-Reactive T Cells based on Expression of Specific Cell Surfa

Posted Jun 05 2013 8:00pm

Description of Invention:
Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell Ig- and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, primarily tumor infiltrating lymphocytes (TIL), is selected and expanded to large quantities, it gets re-infused into the patient via an adoptive cell transfer (ACT) regimen. The key finding for this process is that the most tumor-reactive TIL found in a bulk population of cells obtained from a patient tumor sample reliably exhibit high expression of one or more of these four markers. By selecting cancer attacking TIL from a patient's tumor based on these markers prior to re-infusion, in vitro culture time is reduced to grow up the desired T cells and a more effective anti-cancer T cell product can be produced in comparison to previous TIL immunotherapy approaches.

This new method for selecting tumor-reactive T cells/TIL from tumor samples should help TIL immunotherapy become more GMP compliant and allow greater standardized of the TIL production process to enable more widespread utilization of this personalized cancer treatment approach outside of NIH.



Applications:
  • Personalized ACT immunotherapy to treat human cancers using T cells obtained from a tumor sample
  • Possible integration into a standard procedure for obtaining tumor-reactive T cells/TIL from a tumor as part of a GMP-compliant TIL manufacturing process that gains regulatory approval as a personalized cancer treatment option
  • The immunotherapy component of a combination cancer therapy regimen targeting specific tumor antigens in individual patients
  • More rapid tumor-reactive T cell culturing process for laboratory testing


Advantages:
  • Simpler: Tumor-reactive T cells/TIL can be selected for ACT from a bulk population derived from a tumor sample using common laboratory techniques
  • More rapid: Selection of T cells/TIL based on expression of specific cell surface markers will reduce the culture time for these T cells before re-infusion into the patient to fight the tumor
  • Less screening: This selection method eliminates the need to screen T cells/TIL for autologous tumor recognition before re-infusion into the patient


Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available


Inventors:
Steven A Rosenberg (NCI)
Alena Gros (NCI)


Patent Status:
HHS, Reference No. E-059-2013/0
US, Application No. 61/771,247 filed 01 Mar 2013
PCT, Application No. PCT/US13/38799 filed 30 Apr 2013


Related Technologies:
US, Application No. 61/771,251 filed 01 Mar 2013, Reference No. E-085-2013/0
PCT, Application No. PCT/US13/38813 filed 30 Apr 2013, Reference No. E-085-2013/0
US, Patent No. 8,383,099, Issued 26 Feb 2013, Reference No. E-273-2009/0
US, Application No. 13/742,541 filed 16 Jan 2013, Reference No. E-273-2009/0
US, Patent No. 8,034,334, Issued 11 Oct 2011, Reference No. E-275-2002/1
US, Patent No. 8,287,857, Issued 16 Oct 2012, Reference No. E-275-2002/1
US, Application No. 61/237,889 filed 28 Aug 2009, Reference No. E-273-2009/0


Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize adoptive transfer of tumor infiltrating lymphocytes (TIL) for cancers other than melanoma. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D., at sar@nih.gov or 301-496-4164.


For Licensing Information Please Contact:
Samuel Bish Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: bishse@mail.nih.gov
Phone: 301-435-5282
Fax: 301-402-0220


Ref No: 2571

Updated: 06/2013

Post a comment
Write a comment:

Related Searches